Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baxter International Inc. filings document formal disclosures for a NYSE-listed medtech issuer with common stock and listed global notes. Recent 8-K reports furnish earnings releases, financial-condition updates, dividend declarations, Regulation FD stockholder-engagement materials, executive leadership changes, severance and change-in-control arrangements, and exhibits tied to material corporate actions.
The company’s proxy materials cover board governance, stockholder voting matters, executive compensation and pay-versus-performance disclosures. Debt-related filings describe senior note issuances, supplemental indentures, underwriting arrangements and tender offers, while recurring reports identify registered securities, capital-structure actions and governance controls relevant to Baxter’s medical-device and healthcare-products business.
Baxter International Inc. files Amendment No. 2 to Schedule 13G/A reporting 52,972,914.27 shares of Common Stock beneficially owned, representing 10.3% of the class. The filing names FMR LLC as the holder with sole dispositive power for that amount and notes related power-of-attorney exhibits.
Zielinski Anita A reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. reported that senior vice president and interim CFO Anita A. Zielinski received a one-time special grant of 13,426 shares of common stock as a restricted stock unit award in connection with her additional duties. The award was granted at no cash cost to her and is scheduled to vest on the third anniversary of the grant date, subject to vesting requirements under Baxter’s Second Amended and Restated 2021 Incentive Plan. Following this equity grant and automatic reinvestment of dividends, she directly holds 59,714 shares of Baxter common stock.
Baxter International executive Steven P. Wallace reported a small share disposition related to taxes rather than a market trade. On June 2, 2026, 153 shares of common stock were forfeited to cover tax withholding triggered by the delivery of shares from vested restricted stock units.
These restricted stock units were originally granted on June 2, 2025 and settled one year later. After this tax-withholding disposition, Wallace directly holds 70,128 shares of Baxter common stock, so the event reflects routine compensation and payroll tax handling rather than an open-market sale.
Baxter International executive James Teaff reported a small, routine share disposition tied to taxes on equity compensation. On June 2, 2026, 321 shares of common stock were forfeited at $18.68 per share to cover withholding taxes from vested restricted stock units granted on June 2, 2025. After this tax-withholding event, Teaff directly holds 31,063 shares of Baxter common stock, including shares in the company’s Employee Stock Plan.
The filing is a Form 144 notice concerning proposed sales of Common stock for BAX by an affiliate using Morgan Stanley Smith Barney LLC as broker. The record lists multiple prior open-market purchases with specific trade dates and share counts, and identifies 36,347, $645,235.58, and a reference number 516,469,008.
Baxter International Inc. adopted a new Executive Severance and Change in Control Plan effective May 4, 2026, replacing its prior executive severance program. The plan covers vice presidents and above, including Interim CFO Anita Zielinski and other named executive officers, and provides tiered cash, benefits and outplacement packages for qualifying terminations, with higher multiples and benefits if termination occurs within 24 months after a change in control.
Stockholders at the 2026 annual meeting approved increasing shares reserved under the Second Amended and Restated 2021 Incentive Plan by an additional 20,000,000 common shares and supported executive compensation and all director nominees. They also approved a charter amendment setting a minimum of seven directors, with bylaws specifying a range of seven to twelve directors.
Wilkes David S. reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director David S. Wilkes received a grant of 12,836 fully vested shares of common stock. The grant was recorded at a price of $0.00 per share, reflecting a share award rather than a market purchase. Following this award and automatic reinvestment of dividends, Wilkes now directly holds a total of 37,076 Baxter common shares.
Wendell Amy McBride reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Amy McBride received a grant of 12,836 fully vested shares of common stock. The shares were awarded at no purchase price as part of her compensation and are subject to the applicable grant terms and conditions.
After this award, McBride directly holds 44,235 Baxter shares, a total that includes the automatic reinvestment of dividends. This filing reflects a compensation-related share grant rather than an open-market purchase or sale.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Nancy M. Schlichting reported an equity compensation grant of common stock. On May 5, 2026, she received 12,836 fully vested shares of Baxter common stock at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase. Following this grant, her direct holdings increased to 34,994 shares of common stock. The total reported share balance includes the automatic reinvestment of dividends.
MORRISON PATRICIA reported acquisition or exercise transactions in this Form 4 filing.
Baxter International Inc. director Patricia Morrison received a grant of 12,836 shares of common stock on May 5, 2026. The shares were fully vested at grant and awarded at no cash cost per share, as part of the company’s equity compensation. Following this award, she directly holds 42,386 Baxter common shares, a position that reflects both this grant and the automatic reinvestment of dividends.